Non-adherence to statin therapy: a major challenge for preventive cardiology

Bibliography

• Beyond compliance, adherence, & concordance – supporting the patient’s implementation of optimal treatment. Available from: http://alignmap.com/. [Last accessed 30 April 2009]
   Google Scholar
• World Health Organisation (WHO). Mortality and Health Status 2009. Available from: http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls [Last accessed 30 July 2009]
   Google Scholar
• Yusuf S, Hawken S, Ounpuu S; on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney P, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Ims Health. Top therapeutic classes by global sales. Available from: http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=cec0977ccedc0210VgnVCM100000ed152ca2RCRD&cpsextcurrchannel=1. [Last accessed 30 July 2009]
   Google Scholar
• Shepherd J, Cobbe S, Ford I, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Downs J, Clearfield M, Weis S, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22
   PubMed Web of Science ®Google Scholar
• Ridker P, Danielson E, Fonseca F, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Strandberg T, Pyorala K, Cook T, et al.; for the Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMedGoogle Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• Cannon C, Braunwald E, McCabe C, Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• LaRosa J, Grundy S, Waters D, Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein J, Bittner V, . Treating to New Targets Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54
   PubMed Web of Science ®Google Scholar
• Rockwood K, Kirkland S, Hogan D, Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7
   PubMed Web of Science ®Google Scholar
• Uzzan B, Cohen R, Nicolas P, Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007;40:1581-7
   PubMed Web of Science ®Google Scholar
• Glynn R, Danielson E, Fonseca F, A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-61
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty-two European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37
   PubMed Web of Science ®Google Scholar
• Al-Omran M, Mamdani M, Lindsay T, . Systemic Assessment of Vascular Risk Investigators.Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. J Vasc Surg 2008;48:607-12
   PubMedGoogle Scholar
• Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003
   Google Scholar
• Falvo D. Effective patient education. A guide to increased compliance. 3rd edition. Sudbury MA: Jones & Bartlett; 1999
   Google Scholar
• West of Scotland Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997;18:1718-24
   PubMed Web of Science ®Google Scholar
• Perreault S, Blais L, Lamarre D, Persistence and determinants of statin therapy among middle aged patients for primary and secondary prevention. Br J Clin Pharm 2005;59:564-73.
   PubMed Web of Science ®Google Scholar
• Donnelly L, Doney A, Morris A, Long-term adherence to statin treatment in diabetes. Diab Med 2008;25:850-5
   PubMed Web of Science ®Google Scholar
• Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8 years in a usual care setting. Am J Man Care 2008;14:388-92
   PubMed Web of Science ®Google Scholar
• Benner J, Glynn R, Mogun H, Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61
   PubMed Web of Science ®Google Scholar
• Ho P, Spertus J, Masoudi F, Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-7
   PubMed Web of Science ®Google Scholar
• Eagle K, Kline-Rogers E, Goodman S, Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004;117:73-81
   PubMed Web of Science ®Google Scholar
• Benner J, Tierce J, Ballantyne C, Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharm Econ 2004;22:13-23
   PubMed Web of Science ®Google Scholar
• Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-7
   PubMed Web of Science ®Google Scholar
• Brookhart M, Patrick A, Schweeweiss S, Physician follow-up and provider continuity are associated with long-term medication adherence. A study of the dynamics of statin use. Arch Int Med 2007;167:847-52
   PubMed Web of Science ®Google Scholar
• Bouchard M, Dragomir A, Blais L, Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007;63:698-708
   PubMed Web of Science ®Google Scholar
• Perreault S, Ellia L, Dragomir A, Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med 2009;122:647-55
   PubMed Web of Science ®Google Scholar
• Jackevicius C, Li P, Tu J. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008;117:1028-36
   PubMed Web of Science ®Google Scholar
• Holme I, Szarek M, Cater N, . on behalf of the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. Eur J Cardiovasc Prev Rehab 2009;16:315-20
   PubMedGoogle Scholar
• Peterson A, McGhan W. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 2005;23:13-25
   PubMed Web of Science ®Google Scholar
• Peterson A, McGhan W. A decision analysis model for enhancing medication adherence in patients taking statins. Value Health 2001;4:500 [abstract]
   Google Scholar
• Gibson T, Mark T, Axelsen K, Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006;12:SP11-19
   PubMed Web of Science ®Google Scholar
• Goldman D, Joyce G, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care 2006;12:21-8
   PubMed Web of Science ®Google Scholar
• Pletcher M, Lazar L, Bibbins-Domingo K, Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med 2009;150:243-54
   PubMed Web of Science ®Google Scholar
• Gazmararian J, Kripalani S, Miller M, Factors associated with medication refill adherence in cardiovascular-related diseases. J Gen Int Med 2006;21:1215-21
   PubMed Web of Science ®Google Scholar
• Hermans M, Van Mieghem W, Vandenhoven G, Vissers E. Centralized pan-European Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS). Acta Cardiol 2009:64:177-85
   PubMed Web of Science ®Google Scholar
• Goldman D, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007;298:61-9
   PubMed Web of Science ®Google Scholar
• Doshi JA, Zhu J, Lee B, Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009;119:390-7
   PubMed Web of Science ®Google Scholar
• Sung J, Nichol M, Venturini F, Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998;4:1421-30
   PubMed Web of Science ®Google Scholar
• Dormuth C, Patrick A, Shrank W, Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051-7
   PubMed Web of Science ®Google Scholar
• Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005;11:670-4
   PubMed Web of Science ®Google Scholar
• Bauman A, Fardy H, Harris P. Getting it right: why bother with patient-centered care? Med J Aust 2003;179:253-6
   PubMed Web of Science ®Google Scholar
• Baum A, Posluszny D. Health psychology: mapping biobehavioural contributions to health and illness. Annu Rev Psychol 1999;50:137-63
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24
   Web of Science ®Google Scholar
• Bandura A. Health promotion by social cognitive means. Health Educ Behav 2004;31:143-64
   PubMed Web of Science ®Google Scholar
• Fuertes J, Mislowack A, Bennett J, The physician–patient working alliance. Patient Educ Couns 2007;66:29-36
   PubMed Web of Science ®Google Scholar
• Stilley C, Sereika S, Muldoon M, Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-24
   PubMed Web of Science ®Google Scholar
• Molloy G, Perkins-Porras L, Bhattacharyya M, Practical support predicts medication adherence and attendance at cardiac rehabilitation following acute coronary syndrome. J Psychosom Res 2008;65:581-6
   PubMedGoogle Scholar
• McHorney C. The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 2009;25:215-38
   PubMed Web of Science ®Google Scholar
• Teutsch C. Patient–doctor communication. Med Clin North Am 2003;87:1115-45
   PubMed Web of Science ®Google Scholar
• QA & CPD: Quality Assurance and Continuing Professional Development: Program Handbook 2005-2007 Triennium. (2004). South Melbourne, Vic; Royal Australian College of General Practitioners.
   Google Scholar
• Weng H. Does the physician’s emotional intelligence matter? Impacts of the physician’s emotional trust, patient–physician relationship, and satisfaction. Health Care Manage Rev 2008;33:280-8
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14
   PubMed Web of Science ®Google Scholar
• The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008;359:789-99
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Erhardt L, Hobbs F. Public perceptions of cardiovascular risk in five European countries: the react survey. Int J Clin Pract 2002;56:638-44
   PubMed Web of Science ®Google Scholar
• Polednak A. Awareness and use of blood cholesterol tests in 40 – 74-year-olds by educational level. Public Health Rep 1992;107:345-51
   PubMedGoogle Scholar
• Sprafka J, Burke G, Folsom A, Hypercholesterolemia prevalence, awareness, and treatment in blacks and whites: the Minnesota Heart Survey. Prev Med 1989;18:423-32
   PubMedGoogle Scholar
• Blount BW, Brown JB. Retiree awareness of levels of blood pressure and cholesterol. Mil Med 1996;161:683-6
   PubMedGoogle Scholar
• Bairey Merz C, Felando M, Klein J. Cholesterol awareness and treatment in patients with coronary artery disease participating in cardiac rehabilitation. J Cardiopulm Rehabil 1996;16:117-22
   PubMedGoogle Scholar
• Marquez Contreras E, Casado Martinez J, Corchado A, Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Aten Primaria 1998;22:79-84
   PubMedGoogle Scholar
• Casebeer L, Huber C, Bennett N, Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract 2009, doi:10.1186/1471-2296-10-48 (30 June 2009)
   PubMedGoogle Scholar
• Becker MH, Maiman LA. Strategies for enhancing patient compliance. J Community Health 1980;6:113-35
   PubMedGoogle Scholar
• Mahler HI, Kulik JA, Tarazi RY. Effects of a videotape information intervention at discharge on diet and exercise compliance after coronary bypass surgery. J Cardiopulm Rehabil 1999;19:170-7
   PubMedGoogle Scholar
• Thomas H, Maynard C, Wagner G, Eisenstein L. Results from a practice-based lipid clinic model in achieving low density lipoprotein cholesterol goals. N C Med J 2003;63:263-6
   Google Scholar
• Connolly S, Kotseva K, Jennings C, EUROACTION: the achievement of blood pressure, lipid and glucose targets in a cardiovascular prevention programme in general practice – one year results. Lancet 2008;371:1999-2012
   PubMedGoogle Scholar
• Fulmer T, Feldman P, Kim T, An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nurs 1999;25:6-14
   PubMedGoogle Scholar
• Friedman R, Kazis L, Jette A, A telecommunications system for monitoring and counseling patients with hypertension: impact on medication adherence and blood pressure control. Am J Hypertens 1996;9:285-92
   PubMed Web of Science ®Google Scholar
• Friedman R. Automated telephone conversations to assess health behaviour and deliver behavioural interventions. J Med Syst 1998;22:95-102
   PubMedGoogle Scholar
• Lee J, Grace K, Taylor A. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563-71
   PubMed Web of Science ®Google Scholar
• Winland-Brown J, Vallante J. Effectiveness of different medication management approaches on elders' medication adherence. Outcomes Manag Nurs Pract 2000;4:172-6
   PubMedGoogle Scholar
• Muhlestein J, Horne B, Bair T, Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-61
   PubMed Web of Science ®Google Scholar
• Fonarow G, Gawlinski A, Cardin S, Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol 2001;87:819-22
   PubMed Web of Science ®Google Scholar
• Kalia N, Miller L, Nasir K, Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis 2006;185;394-9
   PubMed Web of Science ®Google Scholar
• Bokhour B, Berlowitz D, Long J, Kressin N. How do providers assess antihypertensive medication adherence in medical encounters? J Gen Intern Med 2006;21:577-83
   PubMed Web of Science ®Google Scholar
• Wilson I, Schoen C, Neuman P, Physician–patient communication about prescription medication nonadherence: a 50 state study of America’s seniors. J Gen Intern Med 2007;22:6-12
   PubMed Web of Science ®Google Scholar
• Allen JK, Blumenthal R, Margolis S, Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial. Am Heart J 2002;144:678-86
   PubMed Web of Science ®Google Scholar
• Gambino K, Planavsky L, Gaudette H. Transition toward a nurse practitioner-managed clinic. J Cardiovasc Nurs 2009;24:132-9
   PubMedGoogle Scholar
• Lee J, Grace K, Taylor A. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563-71
   PubMed Web of Science ®Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins. Focus on clinical pharmacokinetics and drug interactions. Circuation 2004;109(Suppl 3):50-7
   Google Scholar
• Jacobson T. Towards ‘pain-free’ statin prescribing: clincial algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83:687-700
   PubMed Web of Science ®Google Scholar
• Liao J. Safety and efficacy of statins in Asians. Am J Cardiol 2007;9:410-14
   Google Scholar
• FDA Public Health Advisory for Crestor (rosuvastatin). Available from: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051756.htm [Last accessed 30 July 2009]
   Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-25
   PubMed Web of Science ®Google Scholar
• Stein E, Ballantyne C, Windler E, Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008;101:490-6
   PubMed Web of Science ®Google Scholar
• Backes J, Carmelo V, Gibson C, Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008;42:341-6
   PubMed Web of Science ®Google Scholar
• Ruisinger J, Backes J, Gibson C, Moriarty P. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009;103:393-4
   PubMed Web of Science ®Google Scholar
• Caso G, Kelly P, McNurlan M, Lawson W. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99:1409-12
   PubMed Web of Science ®Google Scholar
• Young J, Florkowski C, Molyneux S, Effect of coenzyme q10 supplementation on simvastatin-induced myalgia. Am J Cardiol 2007;100:1400-3
   PubMed Web of Science ®Google Scholar
• Ahmed W, Khan N, Glueck C, Low serum 25 (OH) vitamin D levels (< 32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153:11-6
   PubMed Web of Science ®Google Scholar
• Knopp R, Gitter H, Truitt T, Effects ezetimibe; a new cholesterol absorptioon inhibitor on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41
   PubMed Web of Science ®Google Scholar
• Venero C, Venero J, Seip R, Thompson P. Effectiveness of thrice weekly ezetimibe. Am J Cardiol 2008;102:1205-6
   PubMed Web of Science ®Google Scholar
• Rajamani K, Colman PG, Li L, Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780-8
   PubMed Web of Science ®Google Scholar
• Gibbons L, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995;99:378-85
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Koren M, Davidson M, Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
   PubMed Web of Science ®Google Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779-0
   PubMed Web of Science ®Google Scholar
• Becker D, Gordon R, Halbert S, Red rice for dyslipidemia in statin intolerant patients: a randomized trial. Ann Int Med 2009;150:830-9
   PubMed Web of Science ®Google Scholar
• The NHS Confederation. Investing in General Practice: The New General Medical Services Contract. Available from: http://www.bma.org.uk/ap.nsf/NewGMSContract [Last accessed 5 August 2009]
   Google Scholar
• McGovern M, Boroujerdi M, Taylor M, The effect of the UK incentive-based contract on the management of patients with coronary heart disease in primary care. Fam Pract 2008;25:33-9
   PubMed Web of Science ®Google Scholar
• Joy T, Hegele R. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68
   PubMed Web of Science ®Google Scholar